Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Ovarian Neoplasms

  Free Subscription


06.05.2019

2 Ann Oncol
1 BMC Cancer
1 Eur J Obstet Gynecol Reprod Biol
2 Gynecol Oncol
1 Nat Med


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. MATULONIS UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.
    Ann Oncol. 2019 May 2. pii: 5482567. doi: 10.1093.
    PubMed     Text format     Abstract available

  2. COLOMBO N, Sessa C, du Bois A, Ledermann J, et al
    ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger.
    Ann Oncol. 2019 May 2. pii: 5482247. doi: 10.1093.
    PubMed     Text format     Abstract available


    BMC Cancer

  3. MATTE I, Garde-Granger P, Bessette P, Piche A, et al
    Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
    BMC Cancer. 2019;19:406.
    PubMed     Text format     Abstract available


    Eur J Obstet Gynecol Reprod Biol

  4. BOGANI G, Matteucci L, Tamberi S, Ditto A, et al
    RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy.
    Eur J Obstet Gynecol Reprod Biol. 2019;237:93-99.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  5. DANIELE G, Arenare L, Scambia G, Pisano C, et al
    Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
    Gynecol Oncol. 2019 Apr 24. pii: S0090-8258(19)30507.
    PubMed     Text format     Abstract available

  6. LEDERMANN JA
    Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
    Gynecol Oncol. 2019;153:213-214.
    PubMed     Text format    


    Nat Med

  7. STOWER H
    Lymph removal not tied to positive outcomes.
    Nat Med. 2019;25:541.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: